GlassScriptPhysician profile
Eric Blaine Yazel
NPI 1891764726
$864.03
in general payments reported to CMS, 2019-2025
13 companies · $214 in 2025
The $214 reported for 2025 was more than what 84% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.81 · 2022: $188 · 2023: $158 · 2024: $289 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $281.71 | 2022-2025 | Vraylar, Mavyret |
| Teleflex LLC | $110.13 | 2024 | Quikclot |
| Ethicon US, LLC | $107.00 | 2025 | Surgicel Nu-Knit, Evarrest, Dermabond |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.52 | 2022-2025 | Caplyta |
| Gilead Sciences, INC. | $75.34 | 2023-2024 | |
| Zoll Medical Corporation | $62.52 | 2025 | Defibrillator |
| Lilly USA, LLC | $30.19 | 2021-2023 | Mounjaro, Trulicity |
| Vanda Pharmaceuticals INC. | $26.15 | 2024 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $21.16 | 2024 | Trintellix |
| Alkermes, INC. | $20.00 | 2023 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $15.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.44 | 2023 | Quviviq |
| Galderma Laboratories, L.P. | $14.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.